A client, who has developed peritonitis, is receiving gentamicin 1 g IV q8h. The medication is administered on the following schedule: 0600, 1400, and 2200 and is to infuse for 30 minutes. The 1400 dose has begun infusing. When should the peak blood level be drawn?

A. "The patch will work quickly and effectively to manage your pain.": Transdermal patches have a slow onset of action, often taking 12 to 24 hours to reach therapeutic steady-state levels. Promising a "quick" result is medically inaccurate and mismanages the client's expectations for relief. Patches are designed for long-term maintenance rather than rapid acute analgesia.

B. "The patch will give you a longer duration of pain relief especially during sleep.": While true that patches provide long-acting relief, this statement does not address the client's primary concern about adequacy or previous dissatisfaction with sedation. It fails to explain the pharmacokinetic advantage of consistent dosing over intermittent oral boluses. It provides incomplete education regarding the transition.

C. "The patch has creams and oils imbedded in it to prevent friction and shearing which can lead to skin breakdown.": This is a physiological falsehood regarding the construction of transdermal delivery systems. Patches contain a drug reservoir and an adhesive, but they are not designed as skin-protective barriers against mechanical shearing. Their purpose is systemic drug delivery, not localized dermatological protection.

D. "The patch will maintain consistent levels of the drug in your blood. We may be able to supplement with another pain medication until pain control is reached.": Continuous delivery avoids the "peaks" and "troughs" associated with oral meds, which often cause excessive sedation at peak and pain at trough. Informing the client about supplemental "breakthrough" medication provides a safety net during the slow onset period of the transdermal system.

A. Slough: This refers to inflammatory exudate that is typically yellow, tan, or gray and adheres to the wound bed. It consists of dead white blood cells, fibrin, and cellular debris that must be removed for healing. It does not represent new, healthy tissue growth or the proliferative phase.

B. Necrotic tissue: This term encompasses both slough and eschar, representing non-viable tissue that has lost its blood supply. It is often black, brown, or leathery in appearance and inhibits the formation of a healthy wound base. It is the opposite of the "pinkish red" growth described.

C. Granulation tissue: This tissue is composed of new capillaries and connective tissue, giving it a characteristic beefy red or pink granular appearance. It is a hallmark of the proliferative phase of wound healing, indicating successful oxygenation and nutrient delivery. Its presence confirms the wound is progressing toward closure.

D. Reactive hyperemia: This is a transient increase in blood flow to an area following a period of ischemia, manifesting as non-blanchable redness. It occurs in intact skin after pressure is relieved, rather than appearing as new tissue growth within an existing injury. It is a physiological response, not a structural repair.